that Blood Advances paper aligns with earlier autopsy results, and confirmed
SARS-CoV-2+ megakaryocytes are present in lung and brain autopsy tissues from deceased donors who had COVID-19
But heck! We already knew MKs were long-term impacted. This from 2024 https://ashpublications.org/bloodadvances/article/8/11/2777/515445/SARS-CoV-2-infection-modifies-the-transcriptome-of - though in mice gives what I guess should be an obvious outcome, since the immune system isn't open-loop:
Megakaryocytes (MKs), integral to platelet production, predominantly reside in the bone marrow. [...] at peak SARS-CoV-2 viremia, when the disease primarily affected the lungs, MKs were not significantly different from those from healthy mice. Conversely, a significant divergence in the MK transcriptome was observed during systemic inflammation, although SARS-CoV-2 RNA was never detected in the BM, and it was no longer detectable in the lungs. Under these conditions, the MK transcriptional landscape was enriched in pathways associated with histone modifications, MK differentiation, NETosis, and autoimmunity
and autoimmunity
The breadcrumbs are everywhere.
fin/